Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults
The objective of the present study was to investigate the association between angiotensin-converting enzyme (ACE) inhibitor use and cancer incidence (overall, and breast, prostate, and colorectal cancers specifically) in a large representative sample of US adults. Cross-sectional data on cancer diag...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2020-08, Vol.20 (3), p.409-416 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 3 |
| container_start_page | 409 |
| container_title | Clinical and experimental medicine |
| container_volume | 20 |
| creator | Smith, Lee Parris, Christopher Veronese, Nicola Shang, Ce López-Sánchez, Guillermo F. Jacob, Louis Koyanagi, Ai Nottegar, Alessia Jackson, Sarah E. Raupach, Tobias Grabovac, Igor Crichton, Scott Dempsey, Fiona Yang, Lin |
| description | The objective of the present study was to investigate the association between angiotensin-converting enzyme (ACE) inhibitor use and cancer incidence (overall, and breast, prostate, and colorectal cancers specifically) in a large representative sample of US adults. Cross-sectional data on cancer diagnosis, timing of cancer diagnosis, ACE inhibitor use, and other characteristics were extracted from 49 512 adults aged ≥ 20 years participating in the National Health and Nutrition Examination Survey (1999–2016). Multivariable-logistic and propensity score matching (PSM) regressions examined the relationship between pre-diagnosis use of ACE inhibitors and diagnosis of all cancers, and breast, prostate, and colorectal cancers specifically. Overall, we observed an increased likelihood of cancer diagnosis [odds ratio (OR) 1.269, 95% confidence interval (CI) 1.088–1.480] among those who used ACE inhibitors compared to non-ACE inhibitor use, and for prostate cancer diagnosis (OR 1.438, 95% CI 1.090–1.897), after adjusting for age, sex, body mass index, race/ethnicity, educational attainment, physical activity, alcohol drinking status, smoking status, and high blood pressure. PSM regression retrieved more conservative estimates such that the increased likelihood of cancer diagnosis was only observed when comparing ACE inhibitor users with non-drug users (OR 1.022, 95% CI 1.016–1.027). Compared with non-ACE inhibitor use, ACE inhibitor use was associated with an increased risk of prostate cancer. In conclusion, in this large representative sample of US adults, it was found that ACE inhibitor use may have a marginal influence on some cancers. |
| doi_str_mv | 10.1007/s10238-020-00622-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02938433v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2384215054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-324f7c18f398d903b240f0780d362bf0279abb97c869b4ded4fd6444201082bb3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqXwBTggS1zoIXT8J4l9rFZAkVbqgfZs2Y6zdZW1iycpaj89DlmKxKEnjz2_eR69V1XvKXymAN0ZUmBc1sCgBmgZq7sX1TFtFK1Vw-TLQy2lgqPqDeItAG0kh9fVEWeMqrZtjqu8yQmxRu-mkKIZiUFMLpjlhsT66Zf3kZi4C2nyEUOsXYr3Pk8h7oiPjw97T0K8CTZMKZMZfWF74kx0PpM-mF1MGLAg5PoHMf08Tvi2ejWYEf27w3lSXX_9crW5qLeX375vzre1E6CmmjMxdI7KgSvZK-CWCRigk9DzltkBWKeMtapzslVW9L4XQ98KIRhQkMxaflKdrro3ZtR3OexNftDJBH1xvtXLGzDFpeD8nhb208re5fRz9jjpfUDnx9FEn2bUxWfBaAONKOjH_9DbNOdiXaEEE6IVqlsE2Uq5xd_sh6cNKOglPb2mV5YA_Sc93ZWhDwfp2e59_zTyN64C8BXA0oo7n__9_Yzsb4BIpNo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424464971</pqid></control><display><type>article</type><title>Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Smith, Lee ; Parris, Christopher ; Veronese, Nicola ; Shang, Ce ; López-Sánchez, Guillermo F. ; Jacob, Louis ; Koyanagi, Ai ; Nottegar, Alessia ; Jackson, Sarah E. ; Raupach, Tobias ; Grabovac, Igor ; Crichton, Scott ; Dempsey, Fiona ; Yang, Lin</creator><creatorcontrib>Smith, Lee ; Parris, Christopher ; Veronese, Nicola ; Shang, Ce ; López-Sánchez, Guillermo F. ; Jacob, Louis ; Koyanagi, Ai ; Nottegar, Alessia ; Jackson, Sarah E. ; Raupach, Tobias ; Grabovac, Igor ; Crichton, Scott ; Dempsey, Fiona ; Yang, Lin</creatorcontrib><description>The objective of the present study was to investigate the association between angiotensin-converting enzyme (ACE) inhibitor use and cancer incidence (overall, and breast, prostate, and colorectal cancers specifically) in a large representative sample of US adults. Cross-sectional data on cancer diagnosis, timing of cancer diagnosis, ACE inhibitor use, and other characteristics were extracted from 49 512 adults aged ≥ 20 years participating in the National Health and Nutrition Examination Survey (1999–2016). Multivariable-logistic and propensity score matching (PSM) regressions examined the relationship between pre-diagnosis use of ACE inhibitors and diagnosis of all cancers, and breast, prostate, and colorectal cancers specifically. Overall, we observed an increased likelihood of cancer diagnosis [odds ratio (OR) 1.269, 95% confidence interval (CI) 1.088–1.480] among those who used ACE inhibitors compared to non-ACE inhibitor use, and for prostate cancer diagnosis (OR 1.438, 95% CI 1.090–1.897), after adjusting for age, sex, body mass index, race/ethnicity, educational attainment, physical activity, alcohol drinking status, smoking status, and high blood pressure. PSM regression retrieved more conservative estimates such that the increased likelihood of cancer diagnosis was only observed when comparing ACE inhibitor users with non-drug users (OR 1.022, 95% CI 1.016–1.027). Compared with non-ACE inhibitor use, ACE inhibitor use was associated with an increased risk of prostate cancer. In conclusion, in this large representative sample of US adults, it was found that ACE inhibitor use may have a marginal influence on some cancers.</description><identifier>ISSN: 1591-8890</identifier><identifier>ISSN: 1591-9528</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-020-00622-7</identifier><identifier>PMID: 32219665</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiotensin-converting enzyme inhibitors ; Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Blood pressure ; Body mass index ; Breast cancer ; Breast Neoplasms - chemically induced ; Breast Neoplasms - epidemiology ; Colorectal Neoplasms - chemically induced ; Colorectal Neoplasms - epidemiology ; Cross-Sectional Studies ; Diagnosis ; Drinking behavior ; Drug abuse ; Enzymes ; Female ; Health risk assessment ; Hematology ; Humans ; Hypertension ; Incidence ; Internal Medicine ; Life Sciences ; Logistic Models ; Male ; Medical diagnosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Peptidyl-dipeptidase A ; Physical activity ; Prostate cancer ; Prostatic Neoplasms - chemically induced ; Prostatic Neoplasms - epidemiology ; Risk Factors ; Surveys and Questionnaires ; United States - epidemiology</subject><ispartof>Clinical and experimental medicine, 2020-08, Vol.20 (3), p.409-416</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Springer Nature Switzerland AG 2020.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-324f7c18f398d903b240f0780d362bf0279abb97c869b4ded4fd6444201082bb3</citedby><cites>FETCH-LOGICAL-c409t-324f7c18f398d903b240f0780d362bf0279abb97c869b4ded4fd6444201082bb3</cites><orcidid>0000-0001-9605-1467 ; 0000-0002-9897-5273 ; 0000-0002-1698-6666 ; 0000-0002-9328-289X ; 0000-0003-1071-1239 ; 0000-0002-9565-5004 ; 0000-0001-5658-6168 ; 0000-0003-3325-8705</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-020-00622-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-020-00622-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32219665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02938433$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Lee</creatorcontrib><creatorcontrib>Parris, Christopher</creatorcontrib><creatorcontrib>Veronese, Nicola</creatorcontrib><creatorcontrib>Shang, Ce</creatorcontrib><creatorcontrib>López-Sánchez, Guillermo F.</creatorcontrib><creatorcontrib>Jacob, Louis</creatorcontrib><creatorcontrib>Koyanagi, Ai</creatorcontrib><creatorcontrib>Nottegar, Alessia</creatorcontrib><creatorcontrib>Jackson, Sarah E.</creatorcontrib><creatorcontrib>Raupach, Tobias</creatorcontrib><creatorcontrib>Grabovac, Igor</creatorcontrib><creatorcontrib>Crichton, Scott</creatorcontrib><creatorcontrib>Dempsey, Fiona</creatorcontrib><creatorcontrib>Yang, Lin</creatorcontrib><title>Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><addtitle>Clin Exp Med</addtitle><description>The objective of the present study was to investigate the association between angiotensin-converting enzyme (ACE) inhibitor use and cancer incidence (overall, and breast, prostate, and colorectal cancers specifically) in a large representative sample of US adults. Cross-sectional data on cancer diagnosis, timing of cancer diagnosis, ACE inhibitor use, and other characteristics were extracted from 49 512 adults aged ≥ 20 years participating in the National Health and Nutrition Examination Survey (1999–2016). Multivariable-logistic and propensity score matching (PSM) regressions examined the relationship between pre-diagnosis use of ACE inhibitors and diagnosis of all cancers, and breast, prostate, and colorectal cancers specifically. Overall, we observed an increased likelihood of cancer diagnosis [odds ratio (OR) 1.269, 95% confidence interval (CI) 1.088–1.480] among those who used ACE inhibitors compared to non-ACE inhibitor use, and for prostate cancer diagnosis (OR 1.438, 95% CI 1.090–1.897), after adjusting for age, sex, body mass index, race/ethnicity, educational attainment, physical activity, alcohol drinking status, smoking status, and high blood pressure. PSM regression retrieved more conservative estimates such that the increased likelihood of cancer diagnosis was only observed when comparing ACE inhibitor users with non-drug users (OR 1.022, 95% CI 1.016–1.027). Compared with non-ACE inhibitor use, ACE inhibitor use was associated with an increased risk of prostate cancer. In conclusion, in this large representative sample of US adults, it was found that ACE inhibitor use may have a marginal influence on some cancers.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemically induced</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Colorectal Neoplasms - chemically induced</subject><subject>Colorectal Neoplasms - epidemiology</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis</subject><subject>Drinking behavior</subject><subject>Drug abuse</subject><subject>Enzymes</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Incidence</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Peptidyl-dipeptidase A</subject><subject>Physical activity</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - chemically induced</subject><subject>Prostatic Neoplasms - epidemiology</subject><subject>Risk Factors</subject><subject>Surveys and Questionnaires</subject><subject>United States - epidemiology</subject><issn>1591-8890</issn><issn>1591-9528</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxSMEoqXwBTggS1zoIXT8J4l9rFZAkVbqgfZs2Y6zdZW1iycpaj89DlmKxKEnjz2_eR69V1XvKXymAN0ZUmBc1sCgBmgZq7sX1TFtFK1Vw-TLQy2lgqPqDeItAG0kh9fVEWeMqrZtjqu8yQmxRu-mkKIZiUFMLpjlhsT66Zf3kZi4C2nyEUOsXYr3Pk8h7oiPjw97T0K8CTZMKZMZfWF74kx0PpM-mF1MGLAg5PoHMf08Tvi2ejWYEf27w3lSXX_9crW5qLeX375vzre1E6CmmjMxdI7KgSvZK-CWCRigk9DzltkBWKeMtapzslVW9L4XQ98KIRhQkMxaflKdrro3ZtR3OexNftDJBH1xvtXLGzDFpeD8nhb208re5fRz9jjpfUDnx9FEn2bUxWfBaAONKOjH_9DbNOdiXaEEE6IVqlsE2Uq5xd_sh6cNKOglPb2mV5YA_Sc93ZWhDwfp2e59_zTyN64C8BXA0oo7n__9_Yzsb4BIpNo</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Smith, Lee</creator><creator>Parris, Christopher</creator><creator>Veronese, Nicola</creator><creator>Shang, Ce</creator><creator>López-Sánchez, Guillermo F.</creator><creator>Jacob, Louis</creator><creator>Koyanagi, Ai</creator><creator>Nottegar, Alessia</creator><creator>Jackson, Sarah E.</creator><creator>Raupach, Tobias</creator><creator>Grabovac, Igor</creator><creator>Crichton, Scott</creator><creator>Dempsey, Fiona</creator><creator>Yang, Lin</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-9605-1467</orcidid><orcidid>https://orcid.org/0000-0002-9897-5273</orcidid><orcidid>https://orcid.org/0000-0002-1698-6666</orcidid><orcidid>https://orcid.org/0000-0002-9328-289X</orcidid><orcidid>https://orcid.org/0000-0003-1071-1239</orcidid><orcidid>https://orcid.org/0000-0002-9565-5004</orcidid><orcidid>https://orcid.org/0000-0001-5658-6168</orcidid><orcidid>https://orcid.org/0000-0003-3325-8705</orcidid></search><sort><creationdate>20200801</creationdate><title>Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults</title><author>Smith, Lee ; Parris, Christopher ; Veronese, Nicola ; Shang, Ce ; López-Sánchez, Guillermo F. ; Jacob, Louis ; Koyanagi, Ai ; Nottegar, Alessia ; Jackson, Sarah E. ; Raupach, Tobias ; Grabovac, Igor ; Crichton, Scott ; Dempsey, Fiona ; Yang, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-324f7c18f398d903b240f0780d362bf0279abb97c869b4ded4fd6444201082bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemically induced</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Colorectal Neoplasms - chemically induced</topic><topic>Colorectal Neoplasms - epidemiology</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis</topic><topic>Drinking behavior</topic><topic>Drug abuse</topic><topic>Enzymes</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Incidence</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Peptidyl-dipeptidase A</topic><topic>Physical activity</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - chemically induced</topic><topic>Prostatic Neoplasms - epidemiology</topic><topic>Risk Factors</topic><topic>Surveys and Questionnaires</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Lee</creatorcontrib><creatorcontrib>Parris, Christopher</creatorcontrib><creatorcontrib>Veronese, Nicola</creatorcontrib><creatorcontrib>Shang, Ce</creatorcontrib><creatorcontrib>López-Sánchez, Guillermo F.</creatorcontrib><creatorcontrib>Jacob, Louis</creatorcontrib><creatorcontrib>Koyanagi, Ai</creatorcontrib><creatorcontrib>Nottegar, Alessia</creatorcontrib><creatorcontrib>Jackson, Sarah E.</creatorcontrib><creatorcontrib>Raupach, Tobias</creatorcontrib><creatorcontrib>Grabovac, Igor</creatorcontrib><creatorcontrib>Crichton, Scott</creatorcontrib><creatorcontrib>Dempsey, Fiona</creatorcontrib><creatorcontrib>Yang, Lin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Lee</au><au>Parris, Christopher</au><au>Veronese, Nicola</au><au>Shang, Ce</au><au>López-Sánchez, Guillermo F.</au><au>Jacob, Louis</au><au>Koyanagi, Ai</au><au>Nottegar, Alessia</au><au>Jackson, Sarah E.</au><au>Raupach, Tobias</au><au>Grabovac, Igor</au><au>Crichton, Scott</au><au>Dempsey, Fiona</au><au>Yang, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><addtitle>Clin Exp Med</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>20</volume><issue>3</issue><spage>409</spage><epage>416</epage><pages>409-416</pages><issn>1591-8890</issn><issn>1591-9528</issn><eissn>1591-9528</eissn><abstract>The objective of the present study was to investigate the association between angiotensin-converting enzyme (ACE) inhibitor use and cancer incidence (overall, and breast, prostate, and colorectal cancers specifically) in a large representative sample of US adults. Cross-sectional data on cancer diagnosis, timing of cancer diagnosis, ACE inhibitor use, and other characteristics were extracted from 49 512 adults aged ≥ 20 years participating in the National Health and Nutrition Examination Survey (1999–2016). Multivariable-logistic and propensity score matching (PSM) regressions examined the relationship between pre-diagnosis use of ACE inhibitors and diagnosis of all cancers, and breast, prostate, and colorectal cancers specifically. Overall, we observed an increased likelihood of cancer diagnosis [odds ratio (OR) 1.269, 95% confidence interval (CI) 1.088–1.480] among those who used ACE inhibitors compared to non-ACE inhibitor use, and for prostate cancer diagnosis (OR 1.438, 95% CI 1.090–1.897), after adjusting for age, sex, body mass index, race/ethnicity, educational attainment, physical activity, alcohol drinking status, smoking status, and high blood pressure. PSM regression retrieved more conservative estimates such that the increased likelihood of cancer diagnosis was only observed when comparing ACE inhibitor users with non-drug users (OR 1.022, 95% CI 1.016–1.027). Compared with non-ACE inhibitor use, ACE inhibitor use was associated with an increased risk of prostate cancer. In conclusion, in this large representative sample of US adults, it was found that ACE inhibitor use may have a marginal influence on some cancers.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32219665</pmid><doi>10.1007/s10238-020-00622-7</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9605-1467</orcidid><orcidid>https://orcid.org/0000-0002-9897-5273</orcidid><orcidid>https://orcid.org/0000-0002-1698-6666</orcidid><orcidid>https://orcid.org/0000-0002-9328-289X</orcidid><orcidid>https://orcid.org/0000-0003-1071-1239</orcidid><orcidid>https://orcid.org/0000-0002-9565-5004</orcidid><orcidid>https://orcid.org/0000-0001-5658-6168</orcidid><orcidid>https://orcid.org/0000-0003-3325-8705</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-8890 |
| ispartof | Clinical and experimental medicine, 2020-08, Vol.20 (3), p.409-416 |
| issn | 1591-8890 1591-9528 1591-9528 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02938433v1 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - adverse effects Blood pressure Body mass index Breast cancer Breast Neoplasms - chemically induced Breast Neoplasms - epidemiology Colorectal Neoplasms - chemically induced Colorectal Neoplasms - epidemiology Cross-Sectional Studies Diagnosis Drinking behavior Drug abuse Enzymes Female Health risk assessment Hematology Humans Hypertension Incidence Internal Medicine Life Sciences Logistic Models Male Medical diagnosis Medicine Medicine & Public Health Middle Aged Oncology Original Article Peptidyl-dipeptidase A Physical activity Prostate cancer Prostatic Neoplasms - chemically induced Prostatic Neoplasms - epidemiology Risk Factors Surveys and Questionnaires United States - epidemiology |
| title | Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T03%3A41%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cross-sectional%20associations%20between%20angiotensin-converting%20enzyme%20inhibitor%20use%20and%20cancer%20diagnosis%20in%20US%20adults&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Smith,%20Lee&rft.date=2020-08-01&rft.volume=20&rft.issue=3&rft.spage=409&rft.epage=416&rft.pages=409-416&rft.issn=1591-8890&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-020-00622-7&rft_dat=%3Cproquest_hal_p%3E2384215054%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2424464971&rft_id=info:pmid/32219665&rfr_iscdi=true |